NCT06869473

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE2

Sponsor: Gruppo Oncologico del Nord-Ovest

Condition: Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer

Signal summary

Status signal: Low Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

No stop reason available in the current public record.